“The present predicament has exposed some structural weaknesses within the EU’s medicines offer chain as well as a superior dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides stated. She encouraged that supply chain concerns be addressed within an EU pharmaceutical strategy predicted to become introduced by the ti